Advertisement
Singapore markets closed
  • Straits Times Index

    3,224.01
    -27.70 (-0.85%)
     
  • S&P 500

    5,252.94
    +4.45 (+0.08%)
     
  • Dow

    39,762.90
    +2.82 (+0.01%)
     
  • Nasdaq

    16,414.36
    +14.84 (+0.09%)
     
  • Bitcoin USD

    70,778.13
    +654.81 (+0.93%)
     
  • CMC Crypto 200

    885.54
    0.00 (0.00%)
     
  • FTSE 100

    7,967.60
    +35.62 (+0.45%)
     
  • Gold

    2,229.70
    +17.00 (+0.77%)
     
  • Crude Oil

    82.37
    +1.02 (+1.25%)
     
  • 10-Yr Bond

    4.2220
    +0.0260 (+0.62%)
     
  • Nikkei

    40,168.07
    -594.66 (-1.46%)
     
  • Hang Seng

    16,541.42
    +148.58 (+0.91%)
     
  • FTSE Bursa Malaysia

    1,530.60
    -7.82 (-0.51%)
     
  • Jakarta Composite Index

    7,288.81
    -21.28 (-0.29%)
     
  • PSE Index

    6,903.53
    +5.36 (+0.08%)
     

Aurora Cannabis Inc. (ACB) Gains As Market Dips: What You Should Know

In the latest trading session, Aurora Cannabis Inc. (ACB) closed at $8.96, marking a +0.9% move from the previous day. The stock outpaced the S&P 500's daily loss of 0.23%. Elsewhere, the Dow lost 0.01%, while the tech-heavy Nasdaq lost 0.05%.

Heading into today, shares of the company had lost 10.84% over the past month, lagging the Medical sector's loss of 5.45% and the S&P 500's gain of 3.16% in that time.

Wall Street will be looking for positivity from ACB as it approaches its next earnings report date. In that report, analysts expect ACB to post earnings of -$0.05 per share. This would mark a year-over-year decline of 25%. Our most recent consensus estimate is calling for quarterly revenue of $61.42 million, up 382.06% from the year-ago period.

Looking at the full year, our Zacks Consensus Estimates suggest analysts are expecting earnings of -$0.17 per share and revenue of $224.47 million. These totals would mark changes of -241.67% and +417.53%, respectively, from last year.

ADVERTISEMENT

It is also important to note the recent changes to analyst estimates for ACB. These recent revisions tend to reflect the evolving nature of short-term business trends. As a result, we can interpret positive estimate revisions as a good sign for the company's business outlook.

Our research shows that these estimate changes are directly correlated with near-term stock prices. Investors can capitalize on this by using the Zacks Rank. This model considers these estimate changes and provides a simple, actionable rating system.

The Zacks Rank system ranges from #1 (Strong Buy) to #5 (Strong Sell). It has a remarkable, outside-audited track record of success, with #1 stocks delivering an average annual return of +25% since 1988. The Zacks Consensus EPS estimate remained stagnant within the past month. ACB currently has a Zacks Rank of #3 (Hold).

The Medical - Products industry is part of the Medical sector. This group has a Zacks Industry Rank of 94, putting it in the top 37% of all 250+ industries.

The Zacks Industry Rank gauges the strength of our individual industry groups by measuring the average Zacks Rank of the individual stocks within the groups. Our research shows that the top 50% rated industries outperform the bottom half by a factor of 2 to 1.

Make sure to utilize Zacks. Com to follow all of these stock-moving metrics, and more, in the coming trading sessions.


Is your investment advisor fumbling your financial future?
See how you can more effectively safeguard your retirement with a new Special Report, “4 Warning Signs Your Investment Advisor Might Be Sabotaging Your Financial Future.” Click to get your free report.
 
Aurora Cannabis Inc. (ACB) : Free Stock Analysis Report
 
To read this article on Zacks.com click here.